%PDF-1.4
%
31 0 obj
<>
endobj
28 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-09-13T14:04:42Z
2024-03-29T04:28:11-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T04:28:11-07:00
application/pdf
Heather
2003-812.oct
uuid:f83d4dff-1dd1-11b2-0a00-2909275d6100
uuid:f83d4e01-1dd1-11b2-0a00-aa0000000000
endstream
endobj
17 0 obj
<>
endobj
18 0 obj
<>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 7 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 9 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 11 0 R/Type/Page>>
endobj
102 0 obj
[106 0 R]
endobj
103 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
0 0 0 1 K
/GS1 gs
43 72 m
547 72 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 409.3613 53.9844 Tm
(The Journal of Rheumatology 2004; 31:10)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2070)Tj
/T1_2 1 Tf
-0.00011 Tc -0.0022 Tw 10 0 0 10 43 731.1616 Tm
(tion and overall survival. Our experience suggests that renal)Tj
0.02879 Tw 0 -1.2 TD
(involvement, like other manifestations of MAS, has a spec-)Tj
-0.0143 Tw T*
(trum of severity and even severe renal involvement does not)Tj
-0.007 Tw T*
[(always portend a bad prognosis. )17.7 (The clinical presentation of)]TJ
0.0079 Tw T*
(these 3 cases would suggest heterogeneity in the underlying)Tj
0.2327 Tw T*
[(renal pathology)64.8 (. Early treatment with high dose cortico-)]TJ
0.1861 Tw T*
(steroids with or without other immunosuppressive agents)Tj
0.02499 Tw T*
(may be important in determining a good outcome.)Tj
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 50 613.1616 Tm
[(1.)-875.1 (Schneider R, Laxer RM. Systemic onset juvenile rheumatoid)]TJ
1.675 -1.25 Td
(arthritis. Baillieres Clin Rheumatol 1998;12:245-71.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (W)79.9 (allace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome)]TJ
1.675 -1.25 Td
[(and treatment for the 1990s. Rheum Dis Clin North )54.8 (Am)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1991;17:891-905.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Hadchouel M, Prieur )54.8 (AM, Griscelli C. )54.8 (Acute hemorrhagic, hepatic,)]TJ
1.675 -1.25 Td
(and neurologic manifestations in juvenile rheumatoid arthritis:)Tj
T*
(possible relationship to drugs or infection. J Pediatr )Tj
0 Tc 0 Tw T*
(1985;106:561-6.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader)19.7 (-Meunier)]TJ
1.675 -1.25 Td
[(B, Prieur )54.8 (AM. Reactive haemophagocytic syndrome in children)]TJ
33 27.421 Td
[(with inflammatory disorders. )54.8 (A)-220.1 (retrospective study of 24 patients.)]TJ
T*
(Rheumatology \(Oxford\) 2001;40:1285-92.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Sawhney S, )17.7 (W)79.9 (oo P)110.8 (, Murray KJ. Macrophage activation syndrome: a)]TJ
1.675 -1.25 Td
[(potentially fatal complication of rheumatic disorders. )54.8 (Arch Dis)]TJ
0 Tc T*
(Child 2001;85:421-6.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Society )17.7 (W)91.9 (, Got H. Histiocytosis syndromes in children. Lancet)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1987;1:208-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Ravelli )54.8 (A. Macrophage activation syndrome. Curr Opin Rheumatol)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(2002;14:548-52.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Ramanan )54.8 (A)128.9 (V)128.9 (, Baildam EM. Macrophage activation syndrome is)]TJ
1.675 -1.25 Td
(hemophagocytic lymphohistiocytosis\321need for the right )Tj
T*
[(terminology [letter]. J Rheumatol 2002;29:1)36.8 (105.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Athreya BH. Is macrophage activation syndrome a new entity? Clin)]TJ
1.675 -1.25 Td
(Exp Rheumatol 2002;20:121-3.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Emmenegger U, Reimers )54.8 (A, Frey U, et al. Reactive macrophage)]TJ
2.175 -1.25 Td
(activation syndrome: a simple screening strategy and its potential in)Tj
T*
[(early treatment initiation. Swiss Med )17.7 (Wkly 2002;132:230-6.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Reiner )54.8 (AP)110.7 (, Spivak JL. Hematophagic histiocytosis. )54.8 (A)-220.1 (report of 23)]TJ
2.1381 -1.25 Td
(new patients and a review of the literature. Medicine \(Baltimore\))Tj
0 Tc 0 Tw T*
(1988;67:369-88.)Tj
ET
0 0 0 0 k
/GS0 gs
98.25 77.09 396.47 -10.83 re
f*
0.5 w
98.25 77.09 396.47 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
11 0 obj
<>stream
8;Z]!JI]ON#XnLg+67XqQ7K%HY++5_PC#+9BLB<4)HFnSaEMILq^DoEcVe(.k>fh#
Zt^B1AU?b=l)Koh=41'?:0nZdC8=jY,Mqm'3tcp?8O2jT"iDP_L/)%n&p%heG+%rf
g"7HFJh6AW&1QJ
endstream
endobj
15 0 obj
[/Indexed/DeviceRGB 255 14 0 R]
endobj
14 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
85 0 obj
<>
endobj
35 0 obj
<>
endobj
39 0 obj
<>
endobj
43 0 obj
<>
endobj
78 0 obj
<>
endobj
97 0 obj
<>
endobj
42 0 obj
<>
endobj
72 0 obj
<>stream
HLS{PTUeUzRL]FyK,1IVXrsŻ K
.P ( 5KԜ 9:CldE3}wvZ87g9;4B4xIzʌecfݚ(JL+SB^U8m3O tޱ}vOQ{adycmTt1*>.`}1(&טŗKEf˵KvTdΛ%IVA>`*ZI,LyN,&=/lyhQ98,yd1;顦)Z]5UC=MQC9j*JD'ϐCФiB
(kdH<(5TYUCihgP
$[L`L,ޕǸ֓x(fZJ*,^\Kp\g:.,*1?
ϊK,X`1`+~0"GeXHnPQǩhո"0aϾ&nÒ11
Ykx2B2vxawJxU;KKl